Carisbamate in essential tremor: Brief report of a proof of concept study
✍ Scribed by Rodger J. Elble; David M. Biondi; Steve Ascher; Frank Wiegand; Joseph Hulihan
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 587 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double‐blind, cross‐over, placebo‐controlled study of essential tremor. Sixty‐two patients (intent‐to‐treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21‐day treatment periods. The Fahn‐Tolosa‐Marín Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo. © 2010 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract Essential tremor (ET) is a late‐life neurological disease. Mild cognitive deficits as well as an association with prevalent dementia have been reported in recent case–control studies. We determined whether ET was associated with an increased risk of incident dementia. In a population‐ba
Enrolling essential tremor (ET) patients in clinical research can be challenging. Investigators can maximize recruitment by targeting patient subgroups with greater interest in participation. Nothing has been published on factors that are associated with higher levels of interest in participation. T
## Abstract Head tremor is one of the major expressions of essential tremor (ET). It is not well understood why some patients develop head tremor, whereas others do not. A study of the characteristics of patients with head tremor has not been undertaken. Our goal was to estimate the prevalence of h